Botanix Pharmaceuticals (ASX:BOT) Secures A$48M Debt Facility
Botanix Pharmaceuticals (ASX:BOT) secures A$48 million debt facility with Kreos Capital to support Sofdra™ commercialisation and platform expansion.
Category: Healthcare
EBR Systems (ASX:EBR) Completes First US Commercial Implants of WiSE CRT System
EBR Systems (ASX:EBR) completes first US commercial implants of its WiSE CRT System, advancing towards market release and reimbursement in October 2025.
Mayne Pharma Group Limited (ASX:MYX) Updates on Scheme of Arrangement with Cosette
Mayne Pharma (ASX:MYX) updates investors on its Scheme of Arrangement with Cosette, addressing recent regulatory and contractual developments.
Invion Limited (ASX:IVX) Reports Positive Phase I/II Skin Cancer Trial Results
Invion Limited (ASX:IVX) reports positive safety and efficacy results in Phase I/II skin cancer trial, progressing to next study phase.
Noxopharm Limited (ASX:NOX) Receives Approval for HERACLES Clinical Trial
Noxopharm Limited (ASX:NOX) receives ethics approval for its innovative HERACLES clinical trial, advancing new treatments for chronic inflammatory diseases.
Emyria Limited (ASX:EMD) Reports Promising Six-Month PTSD Outcomes and MOU with ANU
Emyria Limited (ASX:EMD) reports promising six-month PTSD treatment outcomes and signs a strategic MOU with ANU to advance mental health research.
Avecho Biotechnology Limited (ASX:AVE) Receives $1.66M R&D Tax Incentive
Avecho Biotechnology Limited (ASX:AVE) receives $1.66M under the R&D Tax Incentive to support its Phase III insomnia trial and commercialization efforts.
Talius Group Limited (ASX:TAL) Announces 10-for-1 Share Consolidation
Talius Group Limited (ASX:TAL) will consolidate its Ordinary Shares on a 10-for-1 basis following shareholder approval, aiming to streamline its capital structure.
HITIQ Ltd (ASX:HIQ) Announces Partnership with AFL Barwon to Expand PROTEQT
A three-year partnership with AFL Barwon aims to expand HITIQ’s PROTEQT concussion management technology to over 25,000 players in regional Victoria.
Neuren Pharmaceuticals (ASX:NEU) Reports Record Financial Performance and Expansion Plans
Neuren Pharmaceuticals (ASX:NEU) reports a record A$166m income in 2024, driven by DAYBUE sales and initiates Phase 3 trials for NNZ-2591.